Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.50 |
| ▸ | RELA | Q04206 | 2/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | FOS | P01100 | 1/20 | 0.50 |
| ▸ | JUN | P05412 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL762042 | 0.86 | HSP90AA1 (0.50) | CSNK1DALDH1A1NFKB1NFKB2RELA | |
| SCHEMBL30996914 | 0.84 | RAB9A (0.56) | CSNK1DALDH1A1NFKB1NFKB2RELA | |
| SCHEMBL1669574 | 0.84 | RAB9A (0.56) | CSNK1DALDH1A1NFKB1NFKB2RELA | |
| SCHEMBL1900971 | 0.83 | NFKB1 (0.52) | CSNK1DALDH1A1NFKB1NFKB2RELA | |
| SCHEMBL762026 | 0.83 | ALDH1A1 (0.51) | CSNK1DALDH1A1NFKB1HSP90AA1KDM4E | |
| SCHEMBL31379759 | 0.83 | ALDH1A1 (0.51) | CSNK1DALDH1A1NFKB1HSP90AA1KDM4E | |
| SCHEMBL8502962 | 0.83 | HSP90AA1 (0.48) | CSNK1DALDH1A1NFKB1NFKB2RELA | |
| SCHEMBL2538924 | 0.83 | HSP90AA1 (0.67) | CSNK1DALDH1A1NFKB1NFKB2RELA | |
| SCHEMBL11790304 | 0.83 | HSP90AA1 (0.48) | CSNK1DALDH1A1NFKB1NFKB2RELA | |
| SCHEMBL9496451 | 0.83 | ALDH1A1 (0.51) | CSNK1DALDH1A1NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188040-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS INC | 2025-06-12 | — | — | US | disclosed |
| EP-4551555-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | Vividion Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| US-12187685-B2 | Pharmaceutical compositions comprising WRN helicase inhibitors | VIVIDION THERAPEUTICS, INC. | 2025-01-07 | — | — | US | disclosed |
| US-20240140915-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. | 2024-05-02 | — | — | US | disclosed |
| US-20240067612-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| WO-2024010782-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| EP-2714041-B1 | ARYLOXYMETHYL CYCLOPROPANE DERIVATIVES AS PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2016-10-19 | — | — | EP | disclosed |
| EP-1486489-B1 | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation | DOW AGROSCIENCES LLC (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-1516874-B1 | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation | DOW AGROSCIENCES LLC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-9051324-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-06-09 | — | — | US | disclosed |
| EP-1234825-A2 | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation | Dow AgroSciences LLC (US) | 2002-08-28 | — | — | EP | disclosed |
| EP-1234826-A2 | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation | Dow AgroSciences LLC (US) | 2002-08-28 | — | — | EP | disclosed |
| EP-1204643-A2 | FUNGICIDAL HETEROCYCLIC AROMATIC AMIDES AND THEIR COMPOSITIONS, METHODS OF USE AND PREPARATION | Dow AgroSciences LLC (US) | 2002-05-15 | — | — | EP | disclosed |
| US-6355660-B1 | HETEROCYCLIC FUNGICIDES SUBSTITUTED WITH AMIDE GROUPS | DOW AGROSCIENCES LLC | 2002-03-12 | — | — | US | disclosed |
| WO-2001014339-A2 | FUNGICIDAL HETEROCYCLIC AROMATIC AMIDES AND THEIR COMPOSITIONS, METHODS OF USE AND PREPARATION | DOW AGROSCIENCES LLC (US) | 2001-03-01 | — | — | WO | disclosed |
| EP-0946559-A2 | IMIDAZOPYRIDAZINES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1999-10-06 | — | — | EP | disclosed |
| US-5935966-A | COMPOUNDS THAT BLOCK THE ACTIVATION OF TRANSCRIPTION FACTORS THROUGH INHIBITION OF A FAMILY OF SPECIFIC KINASES, DECREASING PROINFLAMMATORY PROTEINS TO TREAT AUTOIMMUNE DISEASES AND AS GENERAL ANTIINFLAMMATORY AGENTS | SIGNAL PHARMACEUTICALS, INC. (US) | 1999-08-10 | — | — | US | disclosed |
| WO-1998038171-A1 | PYRIMIDINE CARBOXYLATES AND RELATED COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNAL PHARMACEUTICALS, INC. (US) | 1998-09-03 | — | — | WO | disclosed |
| WO-1998028299-A2 | IMIDAZOPYRIDAZINES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-07-02 | — | — | WO | disclosed |
| WO-1997009325-A1 | PYRIMIDINE CARBOXYLATES AND RELATED COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNAL PHARMACEUTICALS, INC. (US) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067612-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | CSNK1D 1913/4885ALDH1A1 2371/4885NFKB1 1367/4885 |
| US-20240140915-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | CSNK1D 1913/4885ALDH1A1 2371/4885NFKB1 1367/4885 |
| US-12187685-B2 | Pharmaceutical compositions comprising WRN helicase inhibitors | RECQL, BLM, WRN | CSNK1D 1913/4885ALDH1A1 2371/4885NFKB1 1367/4885 |
| US-20250188040-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | CSNK1D 1913/4885ALDH1A1 2371/4885NFKB1 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.